Nuvalent reports Q1 net loss $84.6M; reiterates zidesamtinib pivotal data in H1 2025, NDA by mid-2025

Nuvalent, Inc.

2025-Q1 EPS reported -$1.18

Cash $1.1B at March 31, 2025; expected to fund operations into 2028.
Q1 net loss $84.6M; R&D expense $74.4M, G&A expense $20.4M.
Zidesamtinib pivotal data for TKI pre-treated ROS1+ NSCLC in H1 2025; NDA submission by mid-2025.
Neladalkib pivotal data for TKI pre-treated ALK+ NSCLC by year-end 2025; ALKAZAR Phase 3 start in H1 2025.
Leadership promotions: Ruth Adams to SVP Clinical Ops, Joshua Horan to SVP Chemistry, Jessie Lin to SVP Corporate Strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.